GH Research PLC (NASDAQ:GHRS) Receives $30.86 Average PT from Analysts

GH Research PLC (NASDAQ:GHRS - Get Free Report) has earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the last year is $30.86.

A number of equities analysts recently commented on GHRS shares. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Royal Bank of Canada initiated coverage on shares of GH Research in a research report on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target for the company. Guggenheim started coverage on GH Research in a report on Thursday, March 13th. They set a "buy" rating and a $32.00 price target on the stock. Cantor Fitzgerald initiated coverage on GH Research in a research note on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price objective for the company. Finally, Stifel Nicolaus raised their target price on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th.

GH Research Stock Performance

Shares of GH Research stock traded up $0.81 on Friday, reaching $10.35. The company had a trading volume of 48,194 shares, compared to its average volume of 174,212. The firm has a market cap of $538.23 million, a PE ratio of -13.06 and a beta of 0.84. The firm's 50 day moving average price is $10.29 and its two-hundred day moving average price is $9.70. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. As a group, sell-side analysts predict that GH Research will post -0.8 EPS for the current year.

Institutional Trading of GH Research

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after acquiring an additional 3,092 shares in the last quarter. AdvisorShares Investments LLC increased its position in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after purchasing an additional 4,806 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of GH Research in the 4th quarter valued at about $44,000. Northern Trust Corp boosted its position in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after purchasing an additional 8,641 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new position in GH Research during the 1st quarter worth approximately $142,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).